Down 76%: Is Cortexyme Stock a Bargain?

Down 76%: Is Cortexyme Stock a Bargain?
·3 min read

The biotech's stock took a big hit after its lead product candidate flunked a key clinical trial.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting